Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359689 | 1.00 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6228384 | 0.84 | MAPT (0.59) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6942920 | 0.84 | MAPT (0.59) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL3576783 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL3576787 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL7545268 | 0.82 | MAPT (0.60) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6949716 | 0.81 | MAPT (0.55) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6950497 | 0.81 | MAPT (0.55) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL7680045 | 0.79 | ALDH1A1 (0.59) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL7680050 | 0.79 | ALDH1A1 (0.59) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6114367-A | SUCH AS 3-(3-CYCLOPENTYLOXY-4-METHOXY)PHENYL-2-ISOXAZOLINE-5-HYDROXAMIC ACID; TREATING SEPSIS, SEPTIC SHOCK, INFLAMMATORY BOWEL DISEASE, TUBERCULOSIS, GRAFT VERSUS HOST DISEASE OR CACHEXIA ASSOCIATED WITH AIDS OR CANCER IN A MAMMAL | PFIZER INC (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0730587-B1 | 3-PHENYL-2-ISOXAZOLINES AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5869511-A | Isoxazoline compounds as inhibitors of TNF release | PFIZER INC. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0749428-B1 | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE | PFIZER (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5686434-A | PHOSPHODIESTERASE TYPE IV INHIBITORS | PFIZER INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0730588-B1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0749428-A1 | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE | PFIZER INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0730587-A1 | 3-ARYL-2-ISOXAZOLINES AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0730588-A1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995024398-A1 | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE | PFIZER INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995014681-A1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014680-A1 | 3-ARYL-2-ISOXAZOLINES AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1995-06-01 | — | — | WO | disclosed |